Peptide Cancer Vaccine Market Future Trends Plan, Industry Growth Structure, Features, End Users, Business Opportunities, Worldwide Forecast To 2026

Peptide cancer vaccines aim to activate the immune system to eradicate cancer cells. These vaccines contain the biochemical information that is needed to generate antigen‐specific T cells to elicit anticancer responses and contain one or more short or long amino acid sequences as tumor antigens, combined with vaccine adjuvant. Recent researches conducted using peptide cancer vaccines have resulted in negative outcomes. This in turn has led researchers to consider the approach as outdated and no longer viable for cancer treatment. However, research and development in assessing the critical role of immune adjuvants, modes of vaccine administration, and T cell dynamics has put peptide cancer vaccines in the main stream of approaches for the treatment of various cancers.

For More Information, a Request sample copy of Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1634

Peptide vaccines are easy to synthesize, cost-effective, and essay to apply in clinical practices. Moreover, these vaccines offer flexibility in changing antigen and lower risk of antigen-induced anaphylaxis. These features are expected to boost demand for peptide cancer vaccines over the forecast period. This features have also increased the R&D activities related to peptide cancer vaccines. For instance, in April 2018, Boston Biomedical, Inc. involved in next generation cancer therapeutics, initiated dosing of the first patient in each of two clinical studies to evaluate the results of its affectability by using DSP-7888, an investigational cancer peptide vaccine.

Global Peptide Cancer Vaccine Market Dynamics

Increasing prevalence of cancer and failure of conventional methods in effective treatment of the disease is expected to boost demand for peptide cancer vaccines. For instance, according to the National Cancer Institute, 2016, around 16.8 million new cases of cancer were diagnosed and 595,690 deaths were registered from the disease in the U.S. Moreover, the number of cases is expected to reach 19 million by 2024. According to the World Health Organization (WHO), cancer resulted in around 14 million cases and 8.2 million deaths in 2012, of which majority of the cases were related to lung, colorectal, prostate, cervical, and breast cancer. This scenario is expected to increase demand for peptide cancer vaccines, thereby propelling the market growth.

LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1634

Key players in the market are focused on adopting merger and acquisition strategies to expand their product portfolio. For instance, in May 2018, Merck & Co. invested US$ 125 Million in Moderna Therapeutics. This expansion included partnering on mRNA-5671, Moderna’s mRNA KRAS cancer vaccine and other shared antigen mRNA cancer vaccines. This vaccine includes an mRNA for four most commonly found KRAS mutations, which according to Moderna will cover most of the mutation that occur in non-small-cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. In November 2017, Moderna launched the Phase I KEYNOTE-603 study of mRNA-4157, an mRNA-based personalized cancer vaccine being developed with Merck & Co., through a US$ 100-million-plus mRNA partnership.

Furthermore, in November 2017, TapImmune Inc., a clinical-stage immune-oncology company with ongoing clinical trials in breast and ovarian cancer, announced that the company has enrolled the final patient in randomized Phase 2 clinical study for its novel T-cell vaccine candidate TPIV200 for the treatment of triple-negative breast cancer (TNBC). Increasing number of such clinical trials for peptide cancer vaccines is expected to propel growth of the global peptide cancer vaccine market over the forecast period.

Global Peptide Cancer Vaccine Market – Regional Insights

North America market accounted for the largest share in the global peptide cancer vaccine market, followed by Europe market in 2016. This is attributed to presence of a high number of top pharmaceutical and biotech companies in this region, such as, Pfizer, Inc., Novartis, Merck, GlaxoSmithKline, Roche and many more. Moreover, the rising prevalence of cancer is also expected to foster the market of peptide cancer vaccine market in the near future. According to a National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024.

Moreover, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region to maximize the value on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, and also provides lower cost operational efficiencies. Increasing government investment in research and development also fosters growth of the global peptide cancer vaccine market in Asia Pacific. For instance, in March 2011, the Korean government participated in the Korean National Enterprise for Clinical Trials, to advance the country’s infrastructure for conducting clinical trials, which is expected to launch new peptide cancer vaccine in the market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/peptide-cancer-vaccine-market-1634

Global Peptide Cancer Vaccine Market – Competitive Analysis

Major key players operating in the global peptide cancer vaccine market include, TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Antigen Express, Immatics Biotechnologies, Immatics, Immune Design, Immunomedics, Galena Biopharma, Generex Biotechnology Corporation, and Ultimovacs.

Global Peptide Cancer Vaccine Market – Taxonomy:

By Pipeline Phase:

• Research
• Preclinical
• Phase-I
• Phase-I/II
• Phase-II
• Phase-III

By Application:

• Colorectal Cancer
• Lung Cancer
• Pancreatic Cancer
• Gastric Cancer
• Prostate Cancer
• Breast Cancer

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Other Related News:

CERVICAL CANCER VACCINES MARKET ANALYSIS

CANCER VACCINES MARKET ANALYSIS

IMMUNO-ONCOLOGY DRUGS MARKET ANALYSIS

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.